Salvinorin A analogues PR-37 and PR-38 attenuate compound 48/80-induced itch responses in mice

British Journal of Pharmacology

Volumn 172, Issue 17, 2015, Pages 4331-4341

  Salaga, M ^a   Polepally, P R ^b   Zielinska, M ^a   Marynowski, M ^a   Fabisiak, A ^a   Murawska, N ^a   Sobczak, K ^a   Sacharczuk, M ^c   Do Rego, J C ^d   Roth, B L ^e   Zjawiony, J K ^b   Fichna, J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c INSTITUTE OF GENETICS AND ANIMAL BREEDING   (Poland)

^d UNIVERSITY OF ROUEN   (France)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (3,4 DICHLORO N METHYLPHENYLACETAMIDO) 2 (1 PYRROLIDINYL)ETHYL]PHENOXYACETIC ACID; COMPOUND 48-80; OPIATE AGONIST; PR 37; PR 38; SALVINORIN A; TERPENOID; UNCLASSIFIED DRUG; 2-O-CINNAMOYLSALVINORIN B; 4 METHOXY N METHYLPHENETHYLAMINE; CLERODANE DERIVATIVE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; EXPLORATORY BEHAVIOR; FEMALE; IN VIVO STUDY; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PRURITUS; SCRATCHING; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DOSE RESPONSE;

ANALGESICS, OPIOID; ANIMALS; DITERPENES, CLERODANE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; NARCOTIC ANTAGONISTS; P-METHOXY-N-METHYLPHENETHYLAMINE; PRURITUS;

EID: 84938723247     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13212     Document Type: Article

References (42)

1. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The concise guide to pharmacology 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Benecke H, Lotts T, Stander S, (2013). Investigational drugs for pruritus. Expert Opin Investig Drugs 22: 1167-1179.
3. Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA, (1993). Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 53: 1253-1257.
4. Bigliardi PL, Bigliardi-Qi M, (2014). Peripheral opioids, chapter 18. In:, Carstens E, Akiyama T, (eds). Itch Mechanisms and Treatment. CRC Press: Boca Raton, FL, pp. 1-12.
5. Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, Bigliardi-Qi M, (2009). Opioids and the skin-where do we stand? Exp Dermatol 18: 424-430.
6. Chen C, Fichna J, Laudon M, Storr M, (2014). Antinociceptive effects of novel melatonin receptor agonists in mouse models of abdominal pain. World J Gastroenterol 20: 1298-1304.
7. Dawn AG, Yosipovitch G, (2006). Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 54: 527-531.
8. Fichna J, Schicho R, Janecka A, Zjawiony JK, Storr M, (2009a). Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. Drug News Perspect 22: 383-392.
9. Fichna J, Schicho R, Andrews CN, Bashashati M, Klompus M, McKay DM, et al. (2009b). Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors. Neurogastroenterol Motil 21: 1326-e128.
10. Fichna J, Dicay M, Lewellyn K, Janecka A, Zjawiony JK, MacNaughton WK, et al. (2012). Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. Inflamm Bowel Dis 18: 1137-1145.
11. Inan S, Cowan A, (2004). Kappa opioid agonists suppress chloroquine-induced scratching in mice. Eur J Pharmacol 502: 233-237.
12. Inan S, Dun NJ, Cowan A, (2009). Nalfurafine prevents 5′-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5′-guanidinonaltrindole-elicited scratching behavior in mice. Neuroscience 163: 23-33.
13. Inui S, (2012). Nalfurafine hydrochloride for the treatment of pruritus. Expert Opin Pharmacother 13: 1507-1513.
14. Kamei J, Nagase H, (2001). Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol 418: 141-145.
15. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
16. Ko MC, (2014). Roles of central opioid receptor subtypes in regulating itch sensation. Peripheral opioids, chapter 25. In:, Carstens E, Akiyama T, (eds). Itch Mechanisms and Treatment. CRC Press: Boca Raton, FL, pp. 1-10.
17. Ko MC, Naughton NN, (2000). An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception. Anesthesiology 92: 795-805.
18. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H, (2010). Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25: 1251-1257.
19. Kuraishi Y, Nagasawa T, Hayashi K, Satoh M, (1995). Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol 275: 229-233.
20. Kuraishi Y, Yamaguchi T, Miyamoto T, (2000). Itch-scratch responses induced by opioids through central mu opioid receptors in mice. J Biomed Sci 7: 248-252.
21. Lim GJ, Ishiuji Y, Dawn A, Harrison B, Kim D, Atala A, et al. (2008). In vitro and in vivo characterization of a novel liposomal butorphanol formulation for treatment of pruritus. Acta Derm Venereol 88: 327-330.
22. Liu XY, Liu ZC, Sun YG, Ross M, Kim S, Tsai FF, et al. (2011). Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 147: 447-458.
23. MacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR, (2013). Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl) 226: 381-392.
24. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
25. Panocka I, Marek P, Sadowski B, (1986). Differentiation of neurochemical basis of stress-induced analgesia in mice by selective breeding. Brain Res 397: 156-160.
26. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
27. Phan NQ, Lotts T, Antal A, Bernhard JD, Stander S, (2012). Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venereol 92: 555-560.
28. Polepally PR, White K, Vardy E, Roth BL, Ferreira D, Zjawiony JK, (2013). Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands. Bioorg Med Chem Lett 23: 2860-2862.
29. Polepally PR, Huben K, Vardy E, Setola V, Mosier PD, Roth BL, et al. (2014). Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor. Eur J Med Chem 85: 818-829.
30. Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, et al. (2012). Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist salvinorin A in humans. Biol Psychiatry 72: 871-879.
31. Salaga M, Sobczak M, Fichna J, (2013). Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract. Drug Discov Today 18: 708-715.
32. Salaga M, Mokrowiecka A, Zakrzewski PK, Cygankiewicz A, Leishman E, Sobczak M, et al. (2014a). Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). J Crohns Colitis 8: 998-1009.
33. Salaga M, Polepally PR, Sobczak M, Grzywacz D, Kamysz W, Sibaev A, et al. (2014b). Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. J Pharmacol Exp Ther 350: 69-78.
34. Salaga M, Polepally PR, Zakrzewski PK, Cygankiewicz A, Sobczak M, Kordek R, et al. (2014c). Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors. Biochem Pharmacol 92: 618-626.
35. Sobczak M, Salaga M, Storr MA, Fichna J, (2014). Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol 49: 24-45.
36. Taylor AM, Roberts KW, Pradhan AA, Akbari HA, Walwyn W, Lutfy K, et al. (2014). Anti-nociception mediated by a kappa opioid receptor agonist is blocked by a delta receptor agonist. Br J Pharmacol 172: 691-703.
37. Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, et al. (2002). Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 435: 259-264.
38. Tominaga M, Ogawa H, Takamori K, (2007). Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 127: 2228-2235.
39. Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, et al. (2003). Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 477: 29-35.
40. Vandeputte C, Taymans JM, Casteels C, Coun F, Ni Y, Van LK, et al. (2010). Automated quantitative gait analysis in animal models of movement disorders. BMC Neurosci 11: 92.
41. Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DY, et al. (2005). Comparison of pharmacological activities of three distinct kappa ligands (salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312: 220-230.
42. Wikstrom B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, et al. (2005). Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 16: 3742-3747.